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A novel autoantibody reacting with the core polypeptides of hnRNP particles has been detected in the serum of a patient 
with systemic lupus eythematosus (SLE) and Sjogren’s syndrome manifestations. Immunoblot analysis, using either rat 
liver or HeLa nuclear extracts as the antigen source, demonstrated that the autoantibody interacts with a specific sub- 
group of the core polypeptides of hnRNP particles, namely 4, B, and B,, but not with A,, C, and C,. 
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1. INTRODUCTION 
In the eucaryotic cell nucleus pre-mRNA 
associates with specific proteins to form 
ribonucleoprotein complexes known as hnRNPs. 
These complexes are considered to be directly in- 
volved in mRNA maturation, and, hence, are cur- 
rently under intensive investigation. 
The major protein components of hnRNPs are 
the core polypeptides, a family of related species 
having many common structural features. In most 
animal cells the core proteins appear on an SDS- 
polyacrylamide gel as a group of three doublets 
(AI-AZ, Bl-Bz, and Cl-Cz), ranging in molecular 
mass from 32-45 kDa [l]. Apart from hnRNA 
and core proteins, a heterogeneous mixture of 
higher (>45 kDa) molecular mass proteins as well 
as U-snRNA molecules are associated with the 
hnRNP particles [2-41. 
U-snRNA molecules (Ul-U6) are known to be 
integral components of lo-12 S small nuclear 
ribonucleoprotein particles (U-snRNPs). These 
particles share a common set of polypeptides but at 
the same time they contain distinct snRNA species, 
Correspondence address: A. Dangli, Biological Research 
Center, The National Hellenic Research Foundation, 48 
Vassileos Constantinou Avenue, Athens 11635, Greece 
as well as unique polypeptides (see [5] and 
references therein). It is also known that snRNPs 
are amongst the most common nuclear antigens 
against which autoantibodies are often developed 
in patients with rheumatic autoimmune disorders 
(review [6]). In particular, snRNPs containing the 
entire set of the nucleoplasmic U-snRNAs 
(VI-U6) or the Ul-snRNA alone are recognized 
by the frequently found anti-Sm and anti-RNP au- 
toantibodies, respectively [7]. These autoan- 
tibodies have proven to be very useful molecular 
probes in studies concerning the structure [8] and 
assembly of snRNP particles [9], their nuclear 
segregation [lo], and role in RNA-splicing (review 
[ 1 l]), and they have been valuable diagnostic tools 
in autoimmune diseases [6]. Recently, other 
distinct anti-snRNP autoantibody specificities 
(anti-U2, anti-U1 +U2), found at a much lower 
frequency, have also been reported [12,13]. 
Moreover, various other RNA-protein complexes 
(i.e. La-ribonucleoprotein) are common antigens 
recognized by autoantibodies (review [6]). 
It is interesting that no autoantibodies directed 
against hnRNP proteins have been described so 
far, despite the fact that hnRNPs are abundant 
nuclear constituents commonly in close association 
with snRNPs. We have searched for the presence 
of autoantibodies against hnRNP components, us- 
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ing hnRNP-enriched nuclear extracts for our initial 
screening. In this report we describe the detection 
of such an autoantibody specificity against core 
polypeptides of 40 S hnRNPs, and discuss its im- 
munoreactive properties. 
2. MATERIALS AND METHODS 
2.1. Sera and antibodies 
The anti-Sm serum and the monoclonal 4F4 antibody used 
were generous gifts of Dr A. Fritz (Base1 Biozentrum) and Dr 
G. Dreyfuss (Northwestern University, Evanston, IL), respec- 
tively. The sera of patients were provided by Professor H. 
Moutsopoulos (School of Medicine, University of Ioannina). 
2.2 Preparation of nuclear extracts 
Rat liver nuclei were extracted with 0.14 M NaCl at pH 8 and 
fractionated on sucrose gradients as described [14]. HeLa 
nuclear extracts were prepared as described in [15]. 
2.3. Immunoblotting 
The protein antigens were obtained from rat liver nuclear ex- 
tracts, isolated 40-50 S monoparticles, and HeLa nuclear ex- 
tracts by precipitation in 2 vols of ethanol, at -20°C 
overnight. 
Protein samples were subjected to electrophoresis either on 
SDS-polyacrylamide gels [16] or on a two-dimensional elec- 
trophoresis system (NEPHGE-SDS/PAGE) [17]. Ampholines 
(pH range 3-10) were from Serva (Heidelberg). 
Transfer of the proteins into nitrocellulose filters, as well as 
the blocking and washing conditions for immunoblotting, was 
exactly as described in [18]. 
2.4. Affinity purification of antibodies 
Antibodies were purified from whole sera following binding 
to their reactive polypeptides immobilized on nitrocellulose 
sheets. 
Rat liver nuclear extracts were submitted to electrophoresis 
on preparative SDS-polyacrylamide slab gels, blotted onto 
nitrocellulose, incubated with serum and washed in the blocking 
solution, as for immunoblotting. Bound antibodies were then 
visualized on strips cut from the sides of the nitrocellulose 
sheet. The corresponding region of the sheet was then excised, 
extensively washed in PBS and the antibodies eluted in 3 M 
KSCN, pH 6.5, for 5 min at room temperature. To the eluate 
1 vol. of PBS buffer was immediately added and the antibodies 
were concentrated by vacuum dialysis against PBS and used as 
such. 
2.5. Indirect immunojhorescence 
HeLa cells were grown on coverslips, rinsed in PBS, fixed in 
methanol (5 min at -20°C) and washed again in PBS. Cells 
were then incubated with the antibody preparation for 30 min 
at room temperature, washed in PBS twice for 10 min each and 
incubated for 30 min with the appropriate anti-human or anti- 
mouse FITC-labelled secondary antibody (DAKO-laboratories, 
Denmark) used at a dilution of 1:40. Microphotography was 
done on a Zeiss Photomicroscope III with Ilford HP5 films. 
3. RESULTS 
3.1. Autoantibody reacting with polypeptides of 
34 and 36 kDa 
In a search for autoantibodies recognizing 
hnRNP components, a group of 46 sera from pa- 
tients suffering from autoimmune disorders were 
screened by protein immunoblotting. The sera 
were obtained from 39 patients suffering from 
SLE (14), MCTD (2), Sjiigren’s syndrome (7), 
scleroderma (6) and rheumatoid arthritis (10). For 
the initial screening, rat liver nuclear extracts 
prepared as described [14] were used as an antigen 
source. Out of the 46 sera screened, one (serum 
64b), from a patient suffering from SLE with 
Sjdgren’s syndrome manifestations showed a uni- 
que pattern and reacted with a polypeptide of ap- 
prox. 34 kDa and a doublet of about 36 kDa 
(fig-l). Since the molecular masses of these reac- 
ting polypeptides were within the expected 
molecular mass range of the core polypeptides 
(32-45 kDa), we performed further analysis in 
order to determine the specificity of this serum. 
3.2. The poiypeptides reacting with serum 64b are 
enriched in the monoparticles region of the 
sucrose gradient 
To characterize the polypeptides recognized by 
serum 64b, we examined their sedimentation pat- 
tern following sucrose gradient fractionation of rat 
liver nuclear extracts. As well known, when frac- 
tionation of nuclear extracts proceeds in the 
absence of exogenously added RNase inhibitors, 
the hnRNP complexes are cleaved to yield smaller 
structures and a population of 40-50 S hnRNPs 
referred to as monoparticles is highly enriched 
(review [19]). Sucrose gradient fractionation of the 
rat liver nuclear extracts is shown in fig.2A where 
a typical profile (ODz54) of such a gradient is 
presented. Monoparticles segregate within the 
40-50 S range of the gradient (region 5 in fig.2A), 
lo-12 S snRNP particles are recovered from the 
light regions of the gradient (regions 2 and 3), 
while heavier than 60 S RNP structures can be 
found in the 50% sucrose cushion (region 6) of the 
gradient [20]. 
The proteins contained in the various pooled 
fractions of the sucrose gradient were analysed 
electrophoretically, and, as expected, region 5 of 
the gradient was characterized by the presence of 
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Fig.1. Immunoblotting using autoimmune serum 64b on 
proteins from a rat liver nuclear extract. The proteins of the 
nuclear extract (ex) were separated on a 10% SDS- 
polyacrylamide gel and either transferred to nitrocelhdose for 
immunoblotting (A), or Coomassie blue-stained (B). Patient 
serum (64b). or serum from a healthy donor (NI) was used in 
a 1: 100 dilution. Protein markers were: bovine serum albumin 
(66 kDa), ovalbumin (45 kDa), carbonic anhydrase (31 kDa) 
and trypsinogen (24 kDa). 
the vast majority of core proteins (fig.2B). The 
64b-antigenic polypeptides were found by im- 
munoblotting on a replica gel to sediment, mainly, 
in the monoparticles fraction, resulting in a 
distribution pattern identical to that of the core 
polypeptides (cf. fig.2B and C). Thus, by the two 
criteria considered so far, that of molecular mass 
and distribution along the sucrose gradient, the 
polypeptides reacting with serum 64b appear to 
belong to the group of core proteins. 
3.3. Only a subgroup of the core polypeptides is 
recognized by serum 64b 
To establish that the 34 and 36 kDa antigenic 
polypeptides are indeed core proteins and, further- 
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more, to determine which of the core protein 
species they represent, we analysed isolated rat 
liver monoparticle proteins by SDS-electrophoresis 
prior to immunoblotting. 
It has already been shown [21,22] that each of 
the protein species (AI-AZ, Br-B2, and Cl-C2) can 
be resolved by this method into a series of easily 
identifiable charge isomers. Proteins of rat liver 
monoparticles were resolved by 2D-gel elec- 
trophoresis, transferred to nitrocellulose and either 
stained (fig.3A) or reacted with serum 64b 
(fig.3B). As seen by comparing fig.3A and B, 64b 
autoantibodies reacted with the charged isomers of 
core proteins AZ, Bi and B2, while no immuno- 
staining could be seen with the A1 and C polypep- 
tides. Since Ai is considerably underrepresented in 
rat liver compared to other cell types, e.g. HeLa 
cells [23], definite conclusions concerning the lack 
of 64b reactivity to Ar cannot be reached by 
analysis of rat liver hnRNPs alone. Therefore, to 
confirm that the only protein species reacting with 
the 64b serum were the AZ, Bl and BZ core 
polypeptides, we performed further 2D- 
immunoblotting analysis using a HeLa nuclear ex- 
tract in which the Al polypeptide is present in an 
amount comparable to A2 1231. The polypeptides 
reacting with serum 64b were again identified as 
being the AZ, Br and B2 charge isomers of the core 
proteins (fig.4). No reaction was observed with 
either the AI polypeptide or the C protein species. 
The use of the HeLa extract offered the 
possibility to directly compare the specificity of the 
autoimmune serum 64b to that of a well 
characterized monoclonal antibody recognizing 
only Cl and CZ core proteins [24]. This monoclonal 
antibody (4F4), although crossreacting with the C 
proteins from different species, does not react with 
mouse [24] or rat liver core proteins (not shown). 
As presented in fig.5, different polypeptides were 
recognized by the two antibodies in HeLa nuclear 
extracts. The 64b serum did not react with the Cl, 
CZ polypeptides, which in turn were the only 
species recognized by 4F4. 
Thus, in HeLa and in rat nuclear extracts, the 
reactivity of 64b was confined to a subgroup (AZ, 
B1 and B2) of the core polypeptides. 
3.4. Cellular distribution of the 64b antigens 
To examine the cellular distribution of 64b an- 
tigenic polypeptides, we performed indirect im- 
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Fig.2. Distribution of the 64b-antigenic polypeptides following fractionation of rat liver nuclear extract on sucrose gradient. (A) 
Absorbance profile (OD& of the nuclear extract run at 55000 x g, 17 h at 4°C on a 15-30% sucrose gradient with a 50% cushion; 
l-6 refers to regions of the gradient from corresponding pooled fractions. The position of migration of rat liver ribosomal subunits 
(40 and 60 S) run on a parallel gradient is also indicated. (B) Coomassie blue-staining of the proteins from the sucrose gradient regions 
(l-6) shown in A, analysed on a 10% SDS-polyacrylamide gel. Protein markers were as in fig.lB. (C) Immunoreaction of serum 64b 
(at a dilution 1 : 100) on a nitrocellulose transfer of a replicate gel shown in B. 
munofluorescence experiments on HeLa cells 
following methanol fixation. The 64b serum ex- 
hibited a homogeneous nuclear staining (fig.6B) 
similar to the pattern obtained with 4F4 antibodies 
(fig.6A; and [24]), as well as with other anti-core 
antibodies [25,26]. 
Since autoimmune antisera are often 
polyspecific [6], it was important to exclude the 
Fig.3. Rat liver core polypeptides recognized by autoimmune serum 64b. The proteins of 40-50 S monoparticles (region 5 of the 
sucrose gradient shown in fig.lA) were separated by two-dimensional electrophoresis (NEPHGE-10% SDS-polyacrylamide), 
transferred onto nitrocellulose and either stained with amido black (A), or immunostained with serum 64b at 1: 100 dilution (B). The 
expected positions for reaction with A1 and C core polypeptides are indicated by the arrowheads. 
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Fig.4. HeLa core polypeptides recognized by autoimmune serum 64b. The proteins present in a HeLa nuclear extract were separated 
by two-dimensional electrophoresis as described in fig.3. (A) Amido black staining of the transferred proteins. (B) Immunostaining 
of a replica blot by serum 64b at 1 : 100 dilution. The expected positions for reaction with At and C core polypeptides are indicated 
by the arrowheads. 
Fig.5. Comparison of the specificities of 64b autoantibodies 
and the 4F4 monoclonal antibodies on HeLa nuclear proteins. 
(A) Proteins of HeLa nuclear extract were separated on a 10% 
SDS-polyacrylamide gel, transferred to nitrocellulose and 
immunostained with NI, and serum 64b (each used at 1: 100 
dilution), or with 4F4 hybridoma cell supemate at 1: 10000 
dilution. (B) Coomassie blue-staining of the HeLa nuclear 
proteins. 
Fig.6. Immunofluorescence staining of HeLa cells fixed with 
methanol by (a) 4F4 hybridoma supernate (1: lOOOO), (b) serum 
64b (1: 100) and (c) anti-Sm serum (1: 100). In b’ and c’ the 
immunofluorescence of affinity purified 64b and antiBm 
antibodies, respectively, is shown. 
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possibility that the 64b staining was due to any 
other antibodies present in the serum. For this pur- 
pose, we repeated the immunofluorescence ex- 
periments using affinity-purified antibodies from 
the 64b serum, as described in section 2. The stain- 
ing pattern obtained by these affinity purified anti- 
core antibodies (fig.6B) resembled that observed 
with whole serum, but it was not so intense. We 
considered this loss of intensity inherent to the af- 
finity purification method, since lower intensities 
were also observed with affinity-purified anti-Sm 
antibodies (cf. fig.6C,C’). 
Therefore, the homogeneous staining pattern 
observed by the 64b antiserum is indeed due to the 
reactivity of anti-core antibodies present in the 
serum. 
4. DISCUSSION 
We have characterized a serum from a patient 
with SLE and Sjogren’s syndrome manifestations, 
which contained autoantibodies directed against 
core polypeptides of hnRNPs. Immunoblotting ex- 
periments revealed that of all core proteins only 
the AZ, Br and BZ polypeptides are recognized. 
Autoantibodies with specificities against several 
ribonucleoprotein components have been de- 
scribed [6]. There are, however, practically no 
reports for autoimmune antibodies with specifi- 
cities for the hnRNP components. In a recent 
study [U] the detection, in the sera of patients with 
mixed connective tissue disease, of autoantibodies 
against hnRNP/RNA components bound to 
nuclear matrix has been reported, but there is no 
further characterization of the antigenic moie- 
ty(ies) involved. Thus, this report presents the first 
case of an autoimmune antibody that recognizes 
core polypeptides of hnRNPs. 
The core polypeptides are evolutionary con- 
served protein species and, possibly because of 
this, of rather poor antigenicity; this is a char- 
acteristic of many cellular components (e.g. DNA, 
histones), against which, however, autoantibodies 
have been elicited. Despite this poor antigenicity, 
antibodies, both conventional and monoclonal, 
against core polypeptides have been experimentally 
developed either by increasing the phylogenetic 
distance between the species involved in immuniza- 
tion [25,26,28], or by immunizing with UV-cross- 
linked hnRNPs 1291. Most of the anti-core an- 
tibodies are shown to react with the entire group of 
the core proteins [25,26], further highlighting the 
structural relationship of these polypeptides. Some 
other anti-core antibodies (to our knowledge all 
monoclonal), recognize subgroups or even single 
core proteins [26,29]. These latter findings are, 
thus, indicative of the presence of particular 
epitopes and they hint at underlying structural dif- 
ferences amongst the core polypeptides, a fact also 
supported by peptide mapping studies [22,30]. 
The autoantibody described here recognizes a 
subgroup of core proteins, namely AZ, Br and Bz 
and not Al, Cr and Cz. This suggests that the an- 
tigenic determinant(s) is (are) not shared between 
these two groups of proteins, in accord with the 
peptide mapping results [22]. Interestingly, the 
core proteins reacting with serum 64b are those 
thought as being positioned internally to Cr, CZ 
and A1 [31]. This poses an interesting question as 
regards the accessibility of the epitopes for the 
generation of the immune response. It should be 
mentioned in this context that the infrequent 
presence of autoantibodies against some internally 
positioned components of the nucleosomes has 
been noted before [32]. 
As already mentioned, the anti-core autoan- 
tibodies were found in one serum out of 46 
originally screened. The sera were obtained from 
patients suffering from various autoimmune 
disorders. The 64b serum containing the anti-core 
antibodies was derived from a patient suffering 
from SLE and Sjiigren’s syndrome manifestations. 
In an additional screening of 14 sera from patients 
with similar clinical findings we failed to identify 
other anti-core autoantibodies. Thus, the presence 
of anti-core autoantibodies in human sera appears 
to represent a rather rare event. Nevertheless, we 
have preliminary evidence for two additional sera 
with autoantibodies of similar specificity from a 
separate sampling of 24 SLE patients. Clearly, fur- 
ther studies are needed in order to draw conclu- 
sions on the frequency of anti-core autoantibodies 
in human sera, as well as to be able to ascribe to 
their presence any possible diagnostic relevance. 
Finally, as has been the case with autoantibodies 
against snRNP components, this new autoan- 
tibody will be a useful probe in studies concerning 
the assembly process of monoparticles, as well as 
the involvement of core polypeptides in pre- 
mRNA maturation processes. 
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